Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced its acquisition of the exclusive U.S. commercialization ...

Harrow Health acquired the United States commercialization rights to four ophthalmic drops from Novartis, according to a press release.The acquisition includes the 1% and 0.5% formulations of ...

Harrow Health, Inc. (NASDAQ: HROW) revealed that it has acquired the exclusive U.S. commercialization rights to four FDA-approved branded eye drops from Novartis (NYSE:NVS) for a one‑time ...

Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced its acquisition of the exclusive U.S. commercialization rights of four FDA-approved ophthalmic ...